James Archie Harrell, Jr. Buys 4,398 Shares of Cerecor Inc (NASDAQ:CERC) Stock

Cerecor Inc (NASDAQ:CERC) VP James Archie Harrell, Jr. bought 4,398 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was purchased at an average cost of $2.85 per share, for a total transaction of $12,534.30. Following the transaction, the vice president now directly owns 8,554 shares of the company’s stock, valued at approximately $24,378.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ:CERC traded up $0.27 during trading hours on Tuesday, reaching $5.25. 164,102 shares of the company were exchanged, compared to its average volume of 80,720. Cerecor Inc has a 1-year low of $2.71 and a 1-year high of $7.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.95 and a quick ratio of 0.91.

Cerecor (NASDAQ:CERC) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. The business had revenue of $5.41 million for the quarter, compared to the consensus estimate of $4.85 million. Cerecor had a negative return on equity of 120.67% and a negative net margin of 226.50%. On average, equities analysts predict that Cerecor Inc will post -0.64 EPS for the current year.

CERC has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cerecor in a research report on Tuesday, May 28th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $8.00 target price on shares of Cerecor in a research report on Monday, May 13th. Maxim Group reaffirmed a “buy” rating and issued a $10.00 target price on shares of Cerecor in a research report on Friday, May 10th. ValuEngine downgraded Cerecor from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Finally, TheStreet downgraded Cerecor from a “c-” rating to a “d+” rating in a research report on Wednesday, May 29th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.67.

A number of large investors have recently modified their holdings of CERC. Vanguard Group Inc lifted its position in shares of Cerecor by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock worth $411,000 after acquiring an additional 8,094 shares during the period. BlackRock Inc. lifted its position in shares of Cerecor by 18.5% in the 4th quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock worth $109,000 after acquiring an additional 5,293 shares during the period. Northern Trust Corp lifted its position in shares of Cerecor by 47.9% in the 4th quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock worth $65,000 after acquiring an additional 6,500 shares during the period. Geode Capital Management LLC lifted its position in shares of Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock worth $306,000 after acquiring an additional 31,951 shares during the period. Finally, Prosight Management LP bought a new position in shares of Cerecor during the 4th quarter worth approximately $994,000. 53.94% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “James Archie Harrell, Jr. Buys 4,398 Shares of Cerecor Inc (NASDAQ:CERC) Stock” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2019/06/12/james-archie-harrell-jr-buys-4398-shares-of-cerecor-inc-nasdaqcerc-stock.html.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Featured Article: Treasury Bonds

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.